Long-term health and aging in people with HIV
Part of Immune system & allergy, Infections clinical trials.
This study follows people with HIV and healthy volunteers over time to see how their health, immune system, and aging change. It aims to find ways to improve long-term care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the earlier TEMPO-1 study.
- You are 18 years old or older.
- You either have HIV or are a healthy person without HIV (to serve as a comparison).
- You are covered by a social security plan (like health insurance).
- You are not under legal guardianship.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
This trial studies how the bacteria in your gut (“microbiome”) relate to frailty (weakness/low physical resilience) in people with HIV who are stably doing well on treatment. It may help researchers understand why some people become frail and how the gut may play a role.
This study tests an experimental medication in healthy volunteers to see how it is processed by the body and whether it is safe. You may not receive direct benefit, but your participation helps find better treatments for people with HIV.
This is an observational study that follows people with HIV who are taking HIV medicines (antiretroviral therapy). It may help researchers understand how treatment is going and what factors relate to doing well on therapy.
This study looks back at people with HIV to understand how often and why heart problems happen. It may help doctors better track heart risk and complications over time.
This study follows adults with HIV over time to compare different groups based on how stable their virus levels are. It may help researchers understand who can safely interrupt treatment and who should stay on it, and how immune health changes.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.